Malin Life Sciences Holdings Ltd, 10% Owner at Poseida Therapeutics, Inc. (PSTX), bought 1,828 shares at $6.90 ($13K) on 2021-12-06, disclosed to the SEC on 2021-12-07.
Open-market purchase of $13k PSTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| Filing → |
| PSTX | BUY | 2021-11-29 | $531K | — | Filing → |
| PSTX | BUY | 2021-11-23 | $363K | — | Filing → |
| PSTX | BUY | 2021-11-18 | $5.5M | — | Filing → |